Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid
Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid
Three separate interventions will be undertaken with the primary outcome of improving pulse
 wave velocity. Initially, age and BMI-matched men and post-menopausal women, all with type 2
 diabetes, will be treated with allopurinol (20 men, 20 women) for 6 months, in order to
 reduce serum uric acid (SUA) concentrations relative to placebo (10 men, 10 women). In a
 second intervention, dietary fructose will be restricted for a period of 6 months in type 2
 diabetes (T2D) subjects who will maintain a stable weight (20 men, 20 women). In a third
 intervention, dietary fructose will be restricted for a period of 6 months in type 2 diabetes
 (T2D) subjects who will achieve a caloric deficit and weight reduction (20 men, 20 women). At
 the beginning and end of each of the studies, measures of arterial stiffness will be combined
 with assessments of endothelial function (flow-mediated dilation and insulin stimulated leg
 blood flow), measurements of systemic inflammation and oxidative stress.
Sedentary, overweight and obese subjects diagnosed with T2D, ages 40-75 years old, will be
 recruited from the local community, via the University of Missouri's Endocrinology Clinic and
 the primary care clinics. During screening, and after consent, anthropometrics (waist
 circumference and body composition) will be obtained and fasting blood will be drawn for
 serum chemistries, A1c, complete blood count, liver and kidney function. Screening will also
 include completion of an oral glucose tolerance test with measurements of arterial stiffness
 and assessment of endothelial function. Following screening, eligible subjects will be
 assigned to one of the four groups (allopurinol, placebo, fructose restriction/isocaloric, or
 fructose restriction/hypocaloric). Allopurinol will be titrated to achieve a target dose of
 300 mg/day. Along with placebo, this arm of the study is double-blinded. A separate group of
 men and women will be assigned to the isocaloric fructose-restriction study in which dietary
 fructose is replaced by starch and body weight is held constant. Lastly, a separate group of
 men and women will be assigned to the hypocaloric fructose-restriction in which baseline
 caloric intake will be reduced by 500 Calories/day while baseline intakes of protein and fat
 will remain constant. The subjects in these groups will not be blinded to the dietary
 treatment but the staff making measurements will be. Subjects in the four groups will be
 matched for age and BMI.
Inclusion Criteria:

 -  Men and women ages 40-75 years at randomization

 -  BMI between 25.1 and 50 kg/m2.

 -  Type 2 diabetes diagnosed > 3 months ago. Patients with T2D will be classified based
 on physician diagnosis.

 Exclusion Criteria:

 -  serum uric acid < 5.5 mg/dL (for medication/allopurinol and isocaloric low-fructose
 diet arm)

 -  habitual diet containing low amount of sugars < 5% of total energy intake

 -  recent CVD event (stroke, heart failure hospitalization, revascularization or acute
 coronary event in the last 12 months).

 -  abnormal thyroid tests or chronic liver disease

 -  stage IV renal disease (GFR <30)

 -  hyperparathyroidism

 -  use of azathioprine

 -  active cancer

 -  autoimmune diseases

 -  excessive alcohol consumption (>14 drinks/week for men, >7 drinks/week for women)

 -  current tobacco use

 -  bodyweight change ≥10% within the last 6 months

 -  history of gout or uncontrolled hypertension

 -  A1C >10 % (only for medication/placebo arm)

 -  Pregnancy or lactation in women (or women not using contraceptives)